Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients

References

• Janssen-Cilag: Prezista (Darunavir). Summary of Product Characteristics [Internet]. [last updated May 11, 2016; cited 2016 Dec 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000707/WC500041756.pdf
   Google Scholar
• EACS Guidelines Version 9.0 [Internet]. [cited 2017 Nov 6]. Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
   Google Scholar
• DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents Oct 2017 [Internet]. 2017 [cited 2017 Oct 25]. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
   Google Scholar
• Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV Med. 2013 Jan;14(1):49–59.10.1111/hiv.2013.14.issue-1
   PubMed Web of Science ®Google Scholar
• Molina J-M, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015 Apr;2(4):e127–e136.10.1016/S2352-3018(15)00027-2
   PubMed Web of Science ®Google Scholar
• Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected With HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 7;161(7):461–471.
   PubMed Web of Science ®Google Scholar
• Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011 Apr;25(7):929–939.10.1097/QAD.0b013e328345ee95
   PubMed Web of Science ®Google Scholar
• Lathouwers E, Wong EY, Luo D, et al. Low HIV-1 resistance in subjects using darunavir once-daily regimens across studies. Poster 505 CROI 2017 Seattle [Internet]. 2017 [cited 2017 Apr 4]. Available from: http://www.croiconference.org/sites/default/files/posters-2017/505_Lathouwers.pdf
   Google Scholar
• El Bouzidi K, White E, Mbisa JL, et al. HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. J Antimicrob Chemother. 2016 Dec;71(12):3487–3494.10.1093/jac/dkw343
   PubMed Web of Science ®Google Scholar
• Antinori A, Meraviglia P, Monforte A d’Arminio, et al. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study. Drug Des Devel Ther. 2016;10:1589–1603.
   PubMed Web of Science ®Google Scholar
• Lackey P, Mills A, Carpio F, et al. Virologic effectiveness of abacavir/lamivudine with darunavir/ritonavir versus other protease inhibitors in treatment-experienced HIV-infected patients in clinical practice. Clin Drug Investig. 2017 Jan;37(1):51–60.10.1007/s40261-016-0456-1
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Imaz A, Perez I, et al. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients. J Antimicrob Chemother. 2014 Sep;69(9):2536–2540.10.1093/jac/dku157
   PubMed Web of Science ®Google Scholar
• Menzaghi B, Ricci E, Carenzi L, et al. Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project). Biomed Pharmacother. 2013 May;67(4):293–298.10.1016/j.biopha.2012.12.005
   PubMed Web of Science ®Google Scholar
• Santos JR, Moltó J, Llibre JM, et al. Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile. PLoS ONE. 2012;7(5):e37442.10.1371/journal.pone.0037442
   PubMed Web of Science ®Google Scholar
• Pasquau J, López-Cortés L, Isabel Mayorga MI, et al. Monotherapy with darunavir/ritonavir is effective and safe in clinical practice. J Int AIDS Soc. 2014;17(4 Suppl 3):19813.10.7448/IAS.17.4.19813
   PubMedGoogle Scholar
• European Medicines Agency Rezolsta [Internet]. [cited 2017 Nov 9]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002819/human_med_001817.jsp&mid=WC0b01ac058001d124
   Google Scholar
• European Medicines Agency Symtuza [Internet]. [cited 2017 Nov 9]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004391/human_med_002165.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Orkin C, Molina J-M, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018 Jan;5(1):e23–e34.10.1016/S2352-3018(17)30179-0
   PubMed Web of Science ®Google Scholar
• Brandt RS, Frederiksen CM. Data collection on adverse events of anti-HIV drugs – the D:A:D STUDY [Internet]. [cited 2016 Dec 16]. Available from: http://www.cphiv.dk/Portals/0/files/Study%20documents/DAD_15th_merger_SOP_v2_April_2014.pdf
   Google Scholar
• Girard PM, Antinori A, Arribas JR, et al. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial. HIV Med. 2017 Jan;18(1):5–12.10.1111/hiv.2017.18.issue-1
   PubMed Web of Science ®Google Scholar
• Arribas JR, Clumeck N, Nelson M, et al. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med. 2012 Aug;13(7):398–405.10.1111/hiv.2012.13.issue-7
   PubMed Web of Science ®Google Scholar
• Häggblom A, Lindbäck S, Gisslén M, et al. HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014. PLOS ONE. 2017;12(2):e0171227.10.1371/journal.pone.0171227
   PubMed Web of Science ®Google Scholar
• Gallant J, Eron J, Orkin C, et al. Week 48 results of AMBER: A Phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naïve HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat (DRV/c) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF). 16th European AIDS Conference; Milan; 2017, PS8/2
   Google Scholar
• Molina J-M, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)) [Internet]. [cited 2014 Nov 5]. Available from: http://www.jiasociety.org/index.php/jias/article/view/19490
   Google Scholar
• Valantin MA, Lambert-Niclot S, Flandre P, et al. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother. 2012 Mar;67(3):691–695.10.1093/jac/dkr504
   PubMed Web of Science ®Google Scholar
• Paton NI, Stöhr W, Arenas-Pinto A, et al. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV. 2015 Oct;2(10):e417–e426.10.1016/S2352-3018(15)00176-9
   PubMed Web of Science ®Google Scholar
• El Bouzidi K, Collier D, Nastouli E, et al. Virological efficacy of PI monotherapy for HIV-1 in clinical practice. J Antimicrob Chemother. 2016 Nov;71(11):3228–3234.10.1093/jac/dkw265
   PubMed Web of Science ®Google Scholar
• Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS Lond Engl. 2010 Jan 16;24(2):223–230.10.1097/QAD.0b013e3283348944
   PubMed Web of Science ®Google Scholar
• Antinori A, Clarke A, Svedhem-Johansson V, et al. Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. AIDS Lond Engl. 2015 Sep 10;29(14):1811–1820.10.1097/QAD.0000000000000778
   PubMed Web of Science ®Google Scholar